The clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis.

Related Articles

The clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis.

Thyroid. 2018 Feb 17;:

Authors: Aghajani M, Graham S, McCafferty C, Shaheed CA, Roberts T, DeSouza P, Yang T, Niles N

Abstract
BACKGROUND: Evidence has shown that PD-L1 overexpression is associated with poor prognosis and resistance to immune therapies in several human cancers. However, data on the prognostic significance of PD-L1 expression in thyroid cancer is limited and remains controversial. In this systematic review and meta-analysis, we aimed to comprehensively evaluate the clinicopathological significance and prognostic value of PD-L1 expression in non-medullary thyroid cancers.
SUMMARY: Electronic databases, including Medline/PubMed, EMBASE and the Cochrane Library, were searched up until July 5th, 2017. In total, 7 comparisons (from 6 articles) comprising 1,421 patients were included in the pooled analysis. There is moderate quality evidence from four studies (n=721) that shows positive PD-L1 expression was significantly associated with poor survival among thyroid cancer patients (pooled Hazard Ratio [HR], 3.73, 95% CI 2.75 to 5.06). Increased PD-L1 expression was also found to be significantly associated with disease recurrence (Odds Ratio [OR] 1.95, 95% CI 1.15 to 3.32) and concurrent thyroiditis (OR=1.65, 95% CI 1.09 to 2.51).
CONCLUSIONS: Our results confirm the prognostic significance of PD-L1 expression in thyroid cancer patients. PD-L1 expression has the potential to be implemented as a prognostic biomarker used to guide clinicians in identifying patients with more aggressive cancers, and for the selection of individuals that would derive durable clinical benefit from anti-PD-1/PD-L1 immunotherapy. Prospective clinical trials will be useful to support these findings.

PMID: 29455638 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2okMMAe